Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
Obstetrics and Gynecology|October 30, 2025
Effect of Prior 9-Valent Human Papillomavirus Vaccination on Subsequent Lower Genital Tract Dysplasia After Cervical Excisional SurgeryElmar Joura, Susanne K Kjaer, Oliver Bautista, et al.
Vaccine|June 17, 2008
Immunogenicity in mice and rabbits of DNA vaccines expressing woodchuck hepatitis virus antigensAlain Luxembourg, Drew Hannaman, Ken Wills, et al.
Vaccine|June 30, 2016
A phase III clinical study to compare the immunogenicity and safety of the 9-valent and quadrivalent HPV vaccines in menPierre Van Damme, Chris J L M Meijer, Dorothee Kieninger, et al.
Human Vaccines & Immunotherapeutics|April 12, 2021
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trialVu Dinh Thiem, Nguyen Dang Quang, Nguyen Hai Tuan, et al.
Contemporary Clinical Trials|November 8, 2016
Design of a long-term follow-up effectiveness, immunogenicity and safety study of women who received the 9-valent human papillomavirus vaccineAlain Luxembourg, Susanne K Kjaer, Mari Nygard, et al.
Human Vaccines & Immunotherapeutics|October 7, 2024
Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian womenSusanne K Kjaer, Thea E Hetland Falkenthal, Karin Sundström, et al.
Clinical and Vaccine Immunology : CVI|April 1, 2011
A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primatesLesley C Dupuy, Michelle J Richards, Barry Ellefsen, et al.
Virology|January 31, 2012
Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporationGhada Khawaja, Thierry Buronfosse, Catherine Jamard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 15, 2021
Anogenital Human Papillomavirus (HPV) Infection, Seroprevalence, and Risk Factors for HPV Seropositivity Among Sexually Active Men Enrolled in a Global HPV Vaccine TrialJoseph E Tota, Anna R Giuliano, Stephen E Goldstone, et al.
Human Vaccines & Immunotherapeutics|June 19, 2015
Phase III, randomized controlled trial in girls 9-15 years old to evaluate lot consistency of a novel nine-valent human papillomavirus L1 virus-like particle vaccineAlain Luxembourg, Edson D Moreira, Rudiwilai Samakoses, et al.
Pageof 7